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Abstract 20 
Background: Anticholinergic medication use is linked with increased cognitive decline, dementia, 21 
falls and mortality, and their use should be limited in older people. Here we estimate the prevalence 22 
of anticholinergic use in England’s older population in 1991 and 2011, and describe changes in use 23 
by participant’s age, sex, cognition and disability. 24 
Methods: We compared data from participants aged 65+ years from the Cognitive Function and 25 
Ageing Studies (CFAS I and II), collected during 1990-1993 (N=7,635) and 2008-2011 (N=7,762).  We 26 
estimated the prevalence of potent anticholinergic use (Anticholinergic Cognitive Burden [ACB] 27 
score=3) and average anticholinergic burden (sum of ACB scores), using inverse probability weights 28 
standardised to the 2011 UK population. These were stratified by age, sex, Mini-Mental State 29 
Examination score, and activities of daily living (ADL) or instrumental ADL (IADL) disability.   30 
Results: Prevalence of potent anticholinergic use increased from 5.7% (95% Confidence Interval [CI] 31 
5.2-6.3%) of the older population in 1990-93 to 9.9% (9.3-10.7%) in 2008-11, adjusted odds ratio of 32 
1.90 (95%CI 1.67 – 2.16). People with clinically significant cognitive impairment (MMSE [Mini Mental 33 
State Examination] 21 or less) were the heaviest users of potent anticholinergic in CFAS II (16.5% 34 
[95%CI 12.0-22.3%]). Large increases in the prevalence of the use medication with ‘any’ 35 
anticholinergic activity were seen in older people with clinically significant cognitive impairment 36 
(53.3% in CFAS I to 71.5% in CFAS II).  37 
Conclusions: Use of potent anticholinergic medications nearly doubled in England’s older population 38 
over 20 years with some of the greatest increases amongst those particularly vulnerable to 39 
anticholinergic side-effects.   40 
Key words: cognitive impairment, anticholinergic burden. 41 
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BACKGROUND 43 
Globally, the population is ageing; In the UK, the proportion of people aged 65 years or over is 44 
projected to increase from 18% in 2017 to 21% by 2027 [1]. Multi-morbidity increases with an ageing 45 
population. This increase has been accompanied by a dramatic rise in polypharmacy with the 46 
proportion of older people taking five or more medication rising four-fold from 12% to 49% over 20 47 
years [2]. The concerns about polypharmacy include interactions, burden on patients, side effects, 48 
and cost.  Many older people frequently receive medicines with anticholinergic properties for 49 
diverse conditions, such as depression, bladder problems, Parkinson’s disease and chronic 50 
obstructive pulmonary disease [3] [4] [5] [6].  51 
 52 
Anticholinergic activity can cause cognitive decline, falls, constipation and daytime drowsiness in 53 
older people [7] [8], and worsen cognition and activities of daily living in people living with 54 
schizophrenia [9]. Greater cumulative use of anticholinergics has been associated with an increased 55 
risk of dementia [10] [11] [12], and mortality [7] . Given these possible associations with long term 56 
outcomes as well as the known immediate adverse anticholinergic effects, it is widely accepted that 57 
these medicines should be avoided in older people where possible [13].  Nevertheless, 58 
anticholinergics remain commonly prescribed.  59 
 60 
Estimates of prevalence of anticholinergic use vary depending on the population, year and definition 61 
of anticholinergic medications. Previous estimates of the prevalence of any anticholinergic use in 62 
older adults have varied from 37%-63% [8] [14], and of ‘potent’ anticholinergic use from 4%-10% [8] 63 
[14] [15]. However, less is known about the impact of anticholinergic effects among groups most 64 
vulnerable to their side-effects such as older people with clinically significant cognitive impairment 65 
including those living with dementia and the very old, because these groups  are commonly excluded 66 
from clinical trials [16] [17].  67 
 68 
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Medications with anticholinergic activity are most commonly available only by prescription, but are 69 
also obtainable over-the-counter. Hence pharmacy dispensing or prescription databases may 70 
underestimate the true prevalence of anticholinergic medication use in the population. Prospective 71 
longitudinal studies, which aim to ascertain participants’ over the counter (OTC) and prescription 72 
medication use, may offer the best opportunities to understand changing patterns in their use. 73 
These prospective longitudinal studies also allow the disaggregation of older populations by health 74 
status and so allow the medication use patterns to be described by physical and cognitive frailty. 75 
 76 
The overall aim of the study was to estimate the prevalence of anticholinergic use in England’s older 77 
population in 1991 and 2011, and describe changes in use by participant’s age, sex, cognition and 78 
disability. 79 
 80 
METHODS 81 
This study compared the prevalence of anticholinergic medication use in the older population of 82 
England using baseline data from two prospective longitudinal studies conducting using identical 83 
methods in 1990/1993 and 2008/2011. The authors assert that all procedures contributing to this 84 
work comply with the ethical standards of the relevant national and institutional committees on 85 
human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures 86 
involving human subjects were approved by local and multi-centre ethical approval (CFAS I: 87 
REC99/5/22, 05/MRE05/37; CFAS II: 07/MRE05/48). 88 
 89 
Data were obtained from the first waves of the Cognitive Function and Ageing Studies: CFAS I and 90 
CFAS II. The CFAS studies are population-based longitudinal studies of ageing, where participants 91 
aged 65 and older were randomly selected from the Family Health Service Authority lists from 92 
specific areas of England and Wales, and include community-based participants and those in long-93 
term care.  94 
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 95 
Potential participants were initially contacted via a letter from their general practice. If the potential 96 
participant provided written informed consent, this was followed by a visit from a trained 97 
interviewer (often from a health-related background) from a team of interviewers. The interview 98 
was conducted in the participants’ place of residence using a structured, computer assisted 99 
interview with direct data entry.  100 
For potential participants considered to lack mental capacity, as per the Mental Capacity Act in the 101 
UK, a request to a key informant, usually a close family member, was made for an interview.  The 102 
interviews were then performed with the assistance of a proxy (often a close family member).  103 
Participants were interviewed between December 1990 and July 1993 (CFAS I), and between 104 
November 2008 and October 2011 (CFAS II).  105 
 106 
Data from three centres from CFAS I of Cambridgeshire (rural), Newcastle (urban) and Nottingham 107 
(urban) were chosen to match the centres in CFAS II. Sampling was stratified by age group (65-74 vs 108 
≥75 years). CFAS I and CFAS II had very similar designs and assessment methods and so medication 109 
use prevalence estimates can be directly compared [18].  The response rate was 80% in CFAS I and 110 
56% in CFAS II [18]. Inverse probability weights are available for both studies to ensure estimates 111 
reflect the age and sex structure of their respective populations. CFAS I and II assessments include 112 
questions about socio-demographic characteristics, residence (long-term care or community-113 
dwelling), medications health and activities of daily living (basic and instrumental), tests of cognitive 114 
function [18]. For data access and study information visit www.cfas.ac.uk. 115 
 116 
Medication Exposure 117 
Medication usage, both prescribed and over the counter, was obtained by self-report. At interview, 118 
participants were asked ‘Are you currently taking any medicines, tablets or injections of any kind, 119 
either you buy yourself or are prescribed by your doctor?’ Where possible packaging was checked, 120 
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with proxies supplying medication information if participants were unable to locate them.   All 121 
prescribed and over the counter medications were recorded using NHS Read codes [2]. Read codes 122 
are a computerised comprehensive coded thesaurus used within the NHS. Prescription and OTC 123 
medication reported was scored 0 to 3 on the Anticholinergic Burden Scale (ACB).  Medication with 124 
in-vitro activity, but no clinically relevant effect are scored 1. Medication with clinically relevant 125 
effects are scored 2 or 3 if associated with delirium. Other medications are scored 0.  For the full list 126 
visit:  127 
https://www.uea.ac.uk/documents/3306616/10940915/Anticholinergics/088bb9e6-3ee2-4b75-128 
b8ce-b2d59dc538c2 129 
Details of the scale development are reported elsewhere [4] [5]. For medications available in the UK, 130 
but not rated on the ACB scale, we applied the same approach used and thus scored (i) all thiazide 131 
diuretics, loop diuretics and antihistamines as 1, (ii) all tricyclic antidepressants as 3, and (iii) all 132 
creams, eye and ear drops as 0. CFAS did not record how medications were obtained, and some 133 
common medications with potential anticholinergic properties such as chlorphenamine, ranitidine, 134 
cimetidine, and codeine products could be prescribed or purchased OTC.   We defined any 135 
anticholinergic use as the use of any medications scoring 1, 2 or 3 on the ACB scale, potent 136 
anticholinergic use as any scoring 3 on the ACB scale, and the anticholinergic burden as the sum of 137 
ACB scores for all medications taken.   138 
 139 
Population subgroups 140 
We estimated anticholinergic use in groups defined by sex, age (grouped in 5-year age bands), 141 
cognitive function (Mini-Mental State Examination [MMSE] ≤21, MMSE 22-25, and MMSE 26-30 142 
points) [19], and disability [measured by impairments in modified Townsend activities of daily living 143 
(ADL) and instrumental activities of daily living (IADL)] [20].   144 
 145 
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 146 
Statistical analysis 147 
We estimated the prevalence of any anticholinergic medication use, potent anticholinergic use and 148 
the average anticholinergic burden, using inverse probability weights that accounted for non-149 
response [18]. To compare cohorts, estimates were standardised to the 2011 UK age and sex 150 
distribution, using 5-year age bands, to account for changes in population structure. Prevalences 151 
were also estimated in the pre-defined population subgroups.   Participants with missing disability or 152 
MMSE data were excluded from those comparisons.   153 
We used logistic regression to estimate odds ratios (OR) for ‘potent’ and ‘any’ anticholinergic use in 154 
CFAS II compared to CFAS I. We used negative binomial regression to estimate the rate ratio 155 
comparing the anticholinergic burden between the two cohorts, as anticholinergic burden was an 156 
over-dispersed discrete variable. The differences between cohorts were adjusted for age, sex and 157 
centre and weighted for non-response. We also tested for interaction effects between subgroups 158 
and CFAS cohort to identify different trends over time among the different groups of the older 159 
population. 160 
Finally, the prevalence of the potent anticholinergic medication by urological, antispasmodic, 161 
antipsychotic, antidepressant, anxiolytic, parkinsonian and antihistamine classes was estimated in 162 
CFAS I and II.  163 
 164 
 165 
RESULTS 166 
 167 
Population characteristics 168 
CFAS I and II included data from 7,635 and 7,762 participants, respectively. Table 1 summarises the 169 
characteristics of CFAS I and II participants. Although the mean Standard Deviation (SD) ages were 170 
similar, 75.3 (7.1) for CFAS I vs 75.7 (7.3) for CFAS II, there was a greater proportion aged over 85 171 
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years in CFAS II. Participants of CFAS II were also slightly more likely to be men and have more IADL 172 
disability than in CFAS I.  173 
INSERT TABLE 1 HERE 174 
Potent anticholinergic use  175 
The overall prevalence of potent anticholinergic use among the over 65s increased from 5.7% (95% 176 
CI 5.2-6.3%) to 9.9% (95% CI 9.3-10.7%) between CFAS I and II.  After adjusting for demographic 177 
differences, the odds ratio for this increase was 1.90 (95% CI 1.67 – 2.16) (table 2).  178 
INSERT TABLE 2 HERE 179 
In CFAS II, 12.8% of women used a potent anticholinergic compared to 7.0% of men.  This is 180 
approximately twice the rate in CFAS I for both sexes.  Potent anticholinergic use was not strongly 181 
related to age; but the heaviest users in CFAS II were those with clinically significant cognitive 182 
impairment (16.5% [95% CI 12.0–22.3%] of those with an MMSE of 21 or less) and more disability, 183 
with 20.8% (95% CI 17.6-24.5%) of the most disabled using a potent anticholinergic compared to 184 
6.3% (95% CI 5.6-7.1%) of those with no disability.  The greatest rate of increase between cohorts 185 
was seen among those with IADL disability (from 6.8% [95% CI 5.4-8.7%] in CFAS I to 15.8% [95% CI 186 
13.8-18.0%] in CFAS II, p-value for interaction = 0.05). 187 
 188 
The increases in potent anticholinergic use were driven by an increased use of anticholinergic 189 
urologicals and antidepressants (table 3). Use of potent anticholinergic urologicals and 190 
antidepressants increased from 0.3% (95% CI 0.2-0.4%) to 2.8% (95% CI 2.4-3.2%) and 4.0% (95% CI 191 
3.6-4.5%) to 5.9% (95% CI 5.4-6.5%) between CFAS I and CFAS II, respectively. The most common 192 
anticholinergic urologicals used in CFAS II were oxybutynin (35% of anticholinergic urological drugs), 193 
tolterodine (31%) and solifenacin (17%), and the most common anticholinergic antidepressant 194 
reported in CFAS II was amitriptyline (69% of anticholinergic antidepressant drugs). 195 
INSERT TABLE 3 HERE 196 
 197 
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Any anticholinergic use  198 
The prevalence of medication use with ‘any’ anticholinergic activity increased from 49.6% (95% CI 199 
48.4-50.7%) to 64.3% (95% CI 63.2-65.4%) between CFAS I and CFAS II (table 2, adjusted OR of 1.25; 200 
95% CI 1.17-1.34).  The greatest increases in use across the 20 years was observed for older 201 
participants (from 50.7% [95% CI 43.5-57.8%] in CFAS I to 75.5% [95% CI 68.9-81.1%] in CFAS II for 202 
those aged 90 years or more, p-value for interaction < 0.001), and in those with clinically significant 203 
cognitive impairment (from 53.3% [95% CI 49.0-57.6%] in CFAS I to 71.5% [95% CI 65.0-77.1%] in 204 
CFAS II for those with an MMSE score of 21 or lower, p-value for interaction = 0.02).  205 
 206 
Anticholinergic burden  207 
The average total anticholinergic burden increased from 0.99 (95% CI 0.96-1.03) in 1991 to 1.11 208 
(95% CI 1.08-1.15) in 2011, adjusted ratio of 1.12 (95% CI 1.07-1.17) (table 4).  209 
INSERT TABLE 4 HERE 210 
Women and older participants had the greatest total burden score, and had experienced the 211 
greatest increases since CFAS I.  For example the mean ACB score increased from 1.05 (95% CI 1.01-212 
1.09) in CFAS I to 1.23 (95% CI 1.18-1.28) in CFAS II for women (p-value for interaction = 0.01), and 213 
from 0.97 (95% CI 0.77-1.17) in CFAS I to 1.36 (95% CI 1.17-1.54) in CFAS II for those aged 90 years or 214 
more (p-value for interaction<0.001). 215 
 216 
 217 
Discussion 218 
The prevalence of potent anticholinergic use in the older population in England nearly doubled 219 
between 1990/93 and 2008/11. After adjustment for demographic variables, we found that 220 
participants in the later study (CFAS II) were 1.9 times more likely to be on potent anticholinergics as 221 
compared to participants in the earlier study (CFAS I). This was mainly due to increases in the 222 
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availability and use of anticholinergic urologicals (common drugs were oxybutynin, solifenacin and 223 
tolterodine) and antidepressants (the most common being amitriptyline). More than one in five of 224 
those with an impairment in activities of daily living, and one in six of those with MMSE less than 21, 225 
indicating clinically significant cognitive impairment including dementia reported use of a potent 226 
anticholinergic medication in CFAS II, both significantly higher than in CFAS I [21]. This is despite 227 
guidance suggesting cautious use of these drugs. Those with IADL disability had the greatest 228 
disproportionate increases in potent anticholinergic use. Women and older participants also had 229 
disproportionately greater increases in total anticholinergic burden between study periods. 230 
 231 
A number of studies have described changes in the rates of anticholinergic prescribing [16] [17]. A 232 
study in Scotland examined changes in the numbers of prescriptions of anticholinergic medications, 233 
from 1995 to 2010, and found a statistically significant but modest increase in the number of older 234 
people prescribed any anticholinergic (20.7% vs 23.7%; p<0.001) [16].  A repeated cross‐sectional 235 
analysis of office‐based outpatient visits for older people in the USA found that the prevalence of 236 
high‐risk anticholinergic prescriptions was stable from 2006 to 2015; it increased from 6.1% in 2006–237 
07 to 6.8% in 2008–09 and decreased to 4.7% by 2014–15 [17]. However, previous studies have not 238 
been able to include over-the-counter medication use nor describe use in vulnerable patient groups; 239 
the US study also only included prescriptions issued by the physician at the sampled visit. 240 
 241 
We observed an increase in anticholinergic urological use between 1991 and 2011, partly because 242 
many of the commonly used urologicals were only introduced in the 1990s, or later. Other studies 243 
have also reported increases in the prescribing of anticholinergic urologicals [16] [22] [23]. A 23% 244 
increased number of new users of anticholinergics for overactive bladder was reported in a UK study 245 
(from 12,598 in 2004 to 15,441 in 2012) [23]. A significant increase in the proportion of women 246 
presenting to physicians with urinary incontinence then prescribed bladder anticholinergics was also 247 
reported in the US (16.7% in 1999 to 35.0% in 2009; p=0.006) [22].  248 
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 249 
Use of anticholinergic antidepressants also increased between CFAS I and II; confirming other studies 250 
[24]. In addition to anticholinergic effects, antidepressants are associated with hyponatraemia [25] 251 
[26]. Even mild hyponatraemia induced by antidepressants may worsen cognition and cause falls 252 
compounding apparent anticholinergic effects [25]. Depression is also an early sign of dementia and 253 
therefore older people with depression may be particularly vulnerable to cognitive anticholinergic 254 
effects [27]. 255 
 256 
Anticholinergics can have a significant impact on morbidity in older people particularly those living 257 
with any form of clinically significant cognitive impairment including dementia [7] [12]. 258 
Anticholinergics can worsen dementia, cause numerous anticholinergic effects, both centrally and 259 
peripherally, and may be associated with an excess mortality [7] [12]. Equally importantly, 260 
anticholinergics could also worsen the quality of life of the older person and any informal (family) 261 
carer [28].  262 
 263 
The large increase in the use of potent anticholinergics among people with clinically significant 264 
cognitive impairment and physical disabilities is particularly concerning.  There is increasing 265 
evidence, from recent research, that such usage is associated with an increased risk of dementia [10] 266 
[11] [12]. Furthermore, anticholinergic cognitive effects are likely to have more severe 267 
consequences, such as medication errors, in people with less cognitive reserve for example 268 
dementia or traumatic brain injury [29]. Medication management itself is an instrumental activity of 269 
daily living with high demands on memory and executive function [30], and so the use of 270 
anticholinergic induced cognitive impairment may increase the risk of both non-adherence to 271 
medication, and medication errors [30] [29]. This in turn will increase dependency on informal carers 272 
worsening the burden on informal carers [31]. 273 
 274 
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Strengths and weaknesses 275 
Frail older people with multi-morbidities including those with dementia are frequently excluded 276 
from controlled trials, and so effectiveness of anticholinergics is rarely directly assessed, and 277 
observational studies are vital for monitoring risks. Strengths of this study include the population-278 
based sampling in CFAS from the same geographic areas 20-years apart and to ascertain key patient 279 
characteristics, cognition and disability associated with medication use. Although most 280 
anticholinergics are prescribed, a further strength of our study was the ability to more accurately 281 
capture the full range of anticholinergic use, by including OTC medications.  282 
 283 
This appropriateness of prescribing was not assessed as part of the CFAS study. The increase in use 284 
of anticholinergics might reflect improvements in diagnosis and better access to treatment for 285 
conditions such as incontinence, depression and pain. Such conditions can be very debilitating, and 286 
for clinicians and patients the key issues is balancing the risks versus the benefits.   287 
 288 
Our study has some limitations. The accuracy of the self-reported medication use and the duration 289 
of treatment is unknown. Although, to increase the accuracy of the reporting, interviewers 290 
requested, where possible, to see the medication packages (and repeat prescription scripts) to enter 291 
correct drug names, we cannot be sure if the participants were adherent to the medication. The data 292 
used is from 1990-1993 and 2008-2011 and therefore we recommend that the study is repeated 293 
with more recent data to examine whether the trends continue.  Studies examining UK trends in 294 
anticholinergic medication use post 2011 are rare. Increased prescribing of anticholinergics for 295 
overactive bladder has been reported until 2012 for adults [23]. Warnings against antipsychotic use 296 
in dementia has decreased prescribing to these patients [32], but we lack information on the general 297 
older population.   Antidepressant prescribing has been increasing from 2013-18, but detail has not 298 
been provided by anticholinergic antidepressants or for older people specifically [33]. 299 
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We used the ACB scale to identify anticholinergic medications, however this is one of 18 different 300 
scales that all vary in their content and how they are derived and how anticholinergic activity is 301 
quantified [34]. However, the scales closely agree on which medications they classify as potently 302 
anticholinergic. The response rate was lower in CFAS II, and it is not clear whether this would under-303 
estimate or over-estimate medication use in this cohort. We used inverse probability weights to 304 
correct age and sex distributions for non-response, and conducted analyses stratified by levels of 305 
cognitive function and disability, and so our findings are unlikely to be biased by differential non-306 
response between cohorts [18]. Our study is descriptive and we did not have sufficient comorbidity 307 
data to sufficiently examine why older people in the various subgroups had increased anticholinergic 308 
use, but increased diagnoses of conditions for which anticholinergics are indicated for is likely a 309 
factor. 310 
 311 
Future Research 312 
Further research is needed to monitor anticholinergic use within vulnerable populations, particularly 313 
older people living with clinically significant cognitive impairment including dementia, in the UK since 314 
2011 and in other countries. We also need a clearer understanding of the relative risk versus benefit 315 
of anticholinergics and in whom the risk is greatest, and effectiveness interventions to reduce the 316 
harm associated with anticholinergics. Interventions to limit the use of inappropriate 317 
anticholinergics require development and testing; a realist approach, which focuses on the key 318 
importance of context and mechanism offers a promising avenue for such intervention development 319 
[35].  320 
 321 
 322 
Conclusions 323 
In summary the use of potent anticholinergic nearly doubled in the older population in England over 324 
an appropriate 20 year period (from 1990/93 to 2008/11), largely due to rising use of 325 
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antidepressants and urologicals. The use of anticholinergics is highest among the most vulnerable 326 
groups including people living with clinically significant cognitive impairment. This raises concerns as 327 
anticholinergic medications are associated with a range of side-effects including cognitive decline. 328 
 329 
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Table 1. Baseline participant characteristics in CFAS I and CFAS II 469 
Demographic 
characteristics 
CFAS I (N=7,635) CFAS II (N=7,762) 
Sex   
Male 3,045 (39.9) 3,534 (45.5) 
Female 4,590 (60.1) 4,228 (54.5) 
Age    
64-69 1,981 (25.9) 1,939 (25.0) 
70-74 1,776 (23.3) 1,873 (24.1) 
75-79 1,725 (22.6) 1,624 (20.9) 
80-84 1,308 (17.1) 1,278 (16.5) 
85-89 615 (8.1) 737 (9.5) 
90+ 230 (3.0) 311 (4.0) 
Centre   
Cambridgeshire 2,601 (34.1) 2,558 (33.0) 
Newcastle 2,522 (33.0) 2,582 (33.3) 
Nottingham 2,512 (32.9) 2,622 (33.8) 
MMSE1   
Median (IQR) 27 (24, 28) 28 (26, 29) 
Disability   
None 5,236 (68.6) 4,975 (64.1) 
IADL disability 1,048 (13.7) 1,495 (19.3) 
ADL-IADL disability 1,267 (16.6) 981 (12.6) 
Residence   
Community-dwelling 7,245 (94.9) 7,565 (97.5) 
Long term care 242 (3.2) 197 (2.5) 
 470 
Cell entries denote n (%) unless otherwise specified 471 
1 139 and 255 participants had missing MMSE data in CFAS I and CFAS II 472 
 473 
Abbreviations: CFAS= Cognitive Function and Ageing Studies, CI=confidence interval, MMSE= Mini-474 
Mental State Examination, ADL= activities of daily living, IADL=instrumental activities of daily living, 475 
SD=standard deviation, IQR=Interquartile range 476 
  477 
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Table 2. Prevalence of any and potent anticholinergic use in CFAS I and CFAS II, by age, sex, cognition and disability  
  Any anticholinergic use Potent anticholinergic use 
Population 
Prevalence % (95% CI) 
Adjusted OR for CFAS II vs 
CFAS Ia 
Prevalence % (95% CI) 
Adjusted OR for CFAS II vs 
CFAS Ia 
CFAS I CFAS II OR (95% CI) pb CFAS I CFAS II OR (95% CI) pb 
Overall 49.6 (48.4, 50.7) 64.3 (63.2, 65.4)  1.25 (1.17, 1.34) <0.001 5.7 (5.2, 6.3)  9.9 (9.3, 10.7) 1.90 (1.67, 2.16) <0.001 
By sex  
    
    
Male 46.7 (44.9, 48.6) 61.3 (59.6, 62.9) 1.00 0.06 3.6 (3.0, 4.4) 6.4 (5.6,7.3) 1.00 0.59 
Female 51.3 (49.8, 52.8) 66.7 (65.2, 68.2) 1.14 (0.99, 1.30)  7.0 (6.3, 7.8) 12.8 (11.7,13.9) 1.08 (0.82, 1.43)  
By age, years 
 
       
64-69  44.4 (42.2,46.6) 53.5 (51.2,55.7) 1.00 <0.001 5.2 (4.3,6.3) 8.0 (6.8,9.5) 1.00 0.49 
70-74 48.2 (45.9,50.6) 62.9 (60.7,65.1) 1.33 (1.11, 1.60) 
  5.9 (4.9,7.1)  9.9 (8.6,11.4)  1.11 (0.76, 1.60)  
75-79 52.8 (50.4,55.2)  68.8 (66.4,71.0) 1.41 (1.17, 1.71) 
 6.0 (4.9,7.2) 11.3 (9.7,13.0) 1.28 (0.88, 1.86)  
80-84 54.3 (51.5,57.0) 73.0 (70.4,75.5) 1.48 (1.20, 1.82) 
 6.8 (5.5,8.3) 11.0 (9.3,12.9)   1.09 (0.73, 1.62)  
85-89 53.8 (49.6,58.0) 72.1 (68.5,75.5) 1.58 (1.21, 2.07) 
 5.3 (3.7,7.5)  11.8 (9.5,14.6)  1.59 (0.95, 2.69)  
90+ 50.7 (43.5,57.8) 75.5 (68.9,81.1) 2.10 (1.36, 3.22) 
 4.1 (2.0,8.0)   9.0 (5.9,13.6)   1.54 (0.63, 3.75)  
By cognition 
    
    
MMSE ≤21   53.3 (49.0, 57.6) 71.5 (65.0, 77.1) 1.00 0.02   11.2 (8.6,14.4) 16.5 (12.0, 22.3) 1.00 0.83 
MMSE 22-25    52.7 (50.2, 55.1) 69.9 (67.1, 72.6) 0.94 (0.70, 1.25)    6.7 (5.6,8.1) 13.4 (11.4,15.6) 1.10 (0.71, 1.70)  
MMSE 26-30   48.6 (47.0, 50.2) 62.8 (61.5, 64.1) 0.76 (0.59, 0.99)     4.5 (3.9,5.2) 8.4 (7.7,9.2) 1.00 (0.68, 1.49)  
By disability         
No impairment 42.4 (40.8,44.0)  56.9 (55.4,58.5) 1.00 0.27  3.8 (3.3, 4.5) 6.3 (5.6, 7.1) 1.00 0.05 
IADL impairment    67.1 (64.0,70.0)    80.4 (78.1,82.5) 1.13 (0.93, 1.36)    6.8 (5.4, 8.7) 
   15.8 (13.8, 
18.0) 
1.46 (1.04, 2.04)  
ADL impairment   71.1 (67.7,74.3)   85.4 (82.3,88.1) 1.15 (0.92, 1.43)      15.8 (13.1,18.9)   20.8 (17.6, 24.5) 0.95 (0.70, 1.29)   
Weighted for nonresponse and standardised by the UK 2011 age population, missing cases excluded 
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Abbreviations: CFAS= Cognitive Function and Ageing Studies, CI=confidence interval, MMSE= Mini-Mental State Examination, ADL= activities of daily living, 
IADL=instrumental activities of daily living 
 
a. Adjusted for age, sex and centre  
b. Global test for the interaction between the covariate and difference in prevalence between CFAS I and CFAS II 
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Table 3. Prevalence of potent anticholinergic use in CFAS I and CFAS II, by drug class 
  
Potent anticholinergic class 1991 CFAS I 2011 CFAS II 
Urological 0.3 (0.2, 0.4) 2.8 (2.4, 3.2) 
Antispasmodic 0.5 (0.3, 0.6) 0.3 (0.2, 0.5) 
Antipsychotic 1.0 (0.8, 1.2) 0.9 (0.7, 1.1) 
Antidepressant 4.0 (3.6, 4.5) 5.9 (5.4, 6.5) 
Anxiolytic N/A 0.2 (0.1, 0.3) 
Parkinsonian 0.2 (0.2, 0.4) 0.1 (0.0, 0.2) 
Antihistamine 0.2 (0.1, 0.3) 0.5 (0.3, 0.7) 
 
Cell entries denote % prevalence (95% confidence intervals) 
Abbreviations: CFAS= Cognitive Function and Ageing Studies  
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Table 4. Average anticholinergic burden in CFAS I and CFAS II, by age, sex, cognition and disability 
 
Population 
Mean ACB sum (95% CI) 
Adjusted rate ratio for CFAS II vs 
CFAS Ia 
CFAS I CFAS II Rate ratio (95% CI) pb 
Overall 0.99 (0.96, 1.03) 1.11 (1.08, 1.15)  1.12 (1.07, 1.17) <0.001 
By sex  
    
Male 0.91 (0.86, 0.95) 0.96 (0.92-1.01) 1.00 0.01 
Female 1.05 (1.01, 1.09) 1.23 (1.18-1.28) 1.12 (1.03, 1.23)  
By age, years     
64-69 0.87 (0.81, 0.92) 0.81 (0.75-0.87) 1.00 <0.001 
70-74 0.97 (0.91, 1.04) 1.10 (1.03-1.66) 1.21 (1.05, 1.38)  
75-79 1.09 (1.02, 1.15) 1.26 (1.18-1.34) 1.24 (1.09, 1.42)  
80-84 1.12 (1.04, 1.20) 1.28 (1.19-1.36) 1.22 (1.06, 1.41)  
85-89 1.07 (0.95, 1.18) 1.37 (1.25-1.49) 1.39 (1.17, 1.66)  
90+ 0.97 (0.77, 1.17) 1.36 (1.17-1.54) 1.53 (1.17, 1.99)  
By cognition    
  
MMSE ≤21 1.29 (1.13, 1.46) 1.32 (1.13, 1.52) 1.00 0.03 
MMSE 22-25 1.09 (1.02, 1.16) 1.38 (1.28, 1.48) 1.11 (0.94, 1.31)  
MMSE 26-30 0.93 (0.89, 0.97) 1.04 (1.01, 1.09) 0.97 (0.83, 1.13)  
By disability 
  
  
No impairment 0.76 (0.72, 0.79) 0.85 (0.81, 0.89) 1.00 0.91 
IADL impairment  1.51 (1.40, 1.61) 1.64 (1.54, 1.74) 1.02 (0.92, 1.13)  
ADL impairment 1.85 (1.71, 1.99) 1.88 (1.74, 2.03) 1.02 (0.91, 1.14)   
Prevalence (95% confidence interval) displayed, weighted for nonresponse and standardised by the 
UK 2011 age population, with missing cases excluded 
Abbreviations: ACB= Anticholinergic Cognitive Burden scale, CFAS= Cognitive Function and Ageing 
Studies, MMSE= Mini-Mental State Examination, ADL= activities of daily living, IADL=instrumental 
activities of daily living 
a Adjusted for age, sex and centre 
b Global test for the interaction between the covariate and ratio of total anticholinergic burden 
between CFAS I and CFAS II 
 
